It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Signaling lymphocytic activation molecule family member 8 (SLAMF8) / B-lymphocyte activator macrophage expressed/CD353 is a member of the CD2 family. SLAMF8 suppresses macrophage function but enhances the growth of neoplastic mast cells via SHP-2. In this study, we found that some anaplastic large cell lymphoma (ALCL) samples were immunohistochemically positive for SLAMF8. However, we found no significant differences between SLAMF8-positive and SLAMF8-negative ALCL samples with respect to age, gender, site, or prognosis. We also identified SLAMF8 expression in ALCL cell lines, Karpas299, and SU-DHL-1. SLAMF8 knockdown decreased the activation of SHP-2 and the growth of these cell lines, and increased the apoptosis of these cell lines. In addition, we observed the interaction between SLAMF8 and SHP-2 in these cell lines using the DuoLink in situ kit. Taken together, these results suggest that SLAMF8 may enhance the growth of ALCL via SHP-2 interaction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Kyoto University Hospital, Department of Diagnostic Pathology, Kyoto, Japan (GRID:grid.411217.0) (ISNI:0000 0004 0531 2775)
2 Kyoto University Hospital, Department of Diagnostic Pathology, Kyoto, Japan (GRID:grid.411217.0) (ISNI:0000 0004 0531 2775); Saiseikai-Noe Hospital, Department of Diagnostic Pathology, Osaka, Japan (GRID:grid.411217.0)
3 Kyoto University Hospital, Department of Diagnostic Pathology, Kyoto, Japan (GRID:grid.411217.0) (ISNI:0000 0004 0531 2775); Kyoto Medical Center, Department of Diagnostic Pathology, Kyoto, Japan (GRID:grid.410835.b)
4 Kyoto University Hospital, Department of Hematology/Oncology, Kyoto, Japan (GRID:grid.411217.0) (ISNI:0000 0004 0531 2775)